TP53 and neoplasm: Using widely validated antibodies and established techniques, our results indicate that patient stratification by combined p53/Bcl-2 phenotype provides tumour stage-independent prognostic information; specifically, that a subset of up to a quarter of colorectal cancer patients display a good prognosis p53(-)/Bcl-2(+) phenotype.